ClinicalTrials.gg
CompletedNCT06697522Updated Nov 20, 2024

Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children

A Phase 3 interventional study of Atropine Sulfate and Placebo in Myopia, sponsored by Ocumension Therapeutics (Suzhou) Co., Ltd. Completed at 1 site in China. Open to participants aged 6 Years to 15 Years. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Ocumension Therapeutics (Suzhou) Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jun 2023, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
6 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Enrollment
26th of 54
148 · median 144
Started
2023
with 7 others
Phase 3
13 of 54
5 open now
Registered
39th of 54
by date

Among the 54 studies testing atropine in Myopia, this one is the 26th largest by enrollment, is one of 8 that started in 2023, is one of 13 in phase 3, and was the 39th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of atropine sulfate eye drops (0.01%) in treating transient myopia induced by near work tasks (NITM) in pediatric subjects.

Read the detailed description

All eligible subjects will be randomly assigned in a 1:1 ratio to either the 0.01% atropine sulfate eye drops group or the atropine sulfate eye drops vehicle placebo control group. Subjects in the treatment group will apply one drop of 0.01% atropine sulfate eye drops to each eye before going to bed at night, while subjects in the control group will apply one drop of the atropine sulfate eye drops vehicle placebo to each eye before going to bed at night. All eligible subjects will be randomly grouped and receive treatment for a period of 12 weeks. All subjects will be followed up according to the same timing and examination schedule. The follow-up time points will be on the 1st day, 14th day, and 12th week after administration, as well as 12 weeks after discontinuation of the medication.

03

Conditions studied

  • Myopia

Browse trials for

Keywords

  • Atropine
04

Who can participate

Ages eligible
6 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For subjects of age between 6 to 8, their parents or legal guardians must provide written ; For 8 year old subjects and above, both the subjects and their legal guardians need to sign the informed consent form.
  2. They must be able to comply with the research requirements, attend all study visits, and be accompanied by their parents/legal guardians.
  3. The age range during the screening period (from Day -14 to Day 0) is 6-15 years, with no gender restrictions.
  4. The optometry results during the screening period should show: a) Myopia between -0.50DS and -4.00DS. b) Astigmatism ≤1.50DC, and less than half of the spherical lens power. c) The initial NITM value (equivalent sphere) for either eye should be ≤-0.40D.
  5. The difference in refractive error between both eyes during the screening period should be ≤1.00D in equivalent spherical lens power.
  6. The best corrected visual acuity (BCVA) for both eyes during the screening period should be ≥0.8 on the standard logarithmic visual acuity chart.
  7. They must be able and willing to avoid using all prohibited medications during the between screening and randomization, as well as during the study period, with no significant risk to the subjects.

Exclusion criteria

Exclusion Criteria:

  1. Known or allergies to atropine sulfate, the study drug, or its components.
  2. abnormal findings on slit-lamp microscopy examination (e.g., cataract) that may affect the measurement of best-corrected visual acuity in either eye at the time of screening, or known clinically significant findings from a previous slit-lamp microscopy examination in either eye.
  3. Clinically significant abnormal findings on direct ophthalmoscopy at the time of screening in either eye, or known previous clinically significant retinal findings in either eye.
  4. Evidence of any ocular motility disorder or restriction of extraocular muscle movement (e.g., nystagmus).
  5. Presence of infectious eye diseases (such as bacterial, viral, or fungal infections).
  6. Active ocular inflammation in either eye or a history of chronic or recurrent ocular inflammation (e.g., moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis).
  7. History of ocular herpes virus infection, iritis, scleritis, or uveitis, regardless of whether it is active at the time of screening.
  8. Abnormal pupillary light reflex and/or amblyopia at the time of screening.
  9. Intraocular pressure (IOP) in either eye \<9mmHg or >21mmHg at the time of screening, or a difference in IOP between both eyes ≥5mmHg, or a previous diagnosis of ocular hypertension or glaucoma, or currently receiving any type of topical IOP-lowering (glaucoma) medication.
  10. Received surgical intervention (ocular or systemic) within 6 months prior to the screening period, or planning to receive surgical intervention during the study period.
  11. Use of any prohibited medication or treatment (ocular or periocular topical medication, systemic medication, injectable medication, and use of any lenses that can slow the progression of myopia) during the specified period before Visit 1. These medications or treatments are also prohibited during the study period. The shortest reasonable for prohibited medications or treatments is:

    1. Any prescription or over-the-counter ophthalmic product (3 days); artificial tears are allowed, but not within 2 hours after the administration of the study drug.
    2. Monoamine oxidase inhibitors (7 days).
    3. Atropine, pirenzepine, or other anticholinergic drugs (60 days).
    4. Any medication affecting the pupil or accommodation (60 days).
    5. Orthokeratology (OK) lenses, rigid gas-permeable contact lenses, bifocal contact lenses, progressive multifocal lenses, multifocal contact lenses, or other lenses that can slow the progression of myopia (90 days).
    6. Monocular glasses and/or monofocal hydrophilic soft contact lenses for myopia correction can be normally used during the study period.
  12. Expected use of ocular or systemic oral during the study period.
  13. Participation in any other experimental treatment study within 30 days before the screening period or during the study period.
  14. History or current disease that makes the subject prone to secondary myopia (e.g., Marfan syndrome, Stickler syndrome) or may affect visual function or development (e.g., diabetes, chromosomal abnormalities).
  15. Presence of any condition or situation that the investigator believes may increase the risk to the subject, confound study data, or severely interfere with the subject's participation in the study, including but not limited to unstable: cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immune, skin, hematological, neurological, or psychiatric diseases.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    0.01% Atropine

    Atropine Sulfate Eye Drops, conc. 0.01%

    Drug: Atropine Sulfate

  • Placebo comparator
    Blank Solvent

    Blank solvent placebo

    Drug: Placebo

Interventions

  • low concentration atropine (0.01%)

    Also known as: Investigational product

  • DrugPlacebo

    Blank comparator

    Also known as: Blank Solvent

06

What researchers measure

Primary outcomes

  1. Change in initial NITM (Nearwork-induced transient myopia) values from baseline to week 12.

    Compare the autorefractor NITM results measured in week 12 of the experimental and control group.

    Time frame: DAY 1 & Week 12

Secondary outcomes

  1. Change from baseline in initial NITM values at week 2 and week 24

    Measure the initial NITM (Near-Induced Transient Myopia) values at the designed time point.

    Time frame: Week 2 and week 24

  2. Initial NITM values

    Test the initial NITM (Near-Induced Transient Myopia) at each time point.

    Time frame: Week 2

  3. Initial NITM values

    Test the initial NITM (Near-Induced Transient Myopia) at each time point.

    Time frame: Week 12

  4. Initial NITM values

    Test the initial NITM (Near-Induced Transient Myopia) at each time point.

    Time frame: Week 24

  5. The difference between the change in initial NITM values

    The difference between the change in initial NITM values from baseline to week 12 and the change from baseline to week 24

    Time frame: Day 1 & Week 12 & Week 24

07

Study locations

1 site
  • Beijing Children's Hospital, Capital Medical University
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Oct 2023, 3 months.

Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 20, 2024
StartActual
Jun 25, 2023
Primary completionActual
Oct 6, 2023
CompletionActual
Mar 26, 2024
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06697522
Lead sponsor
Ocumension Therapeutics (Suzhou) Co., Ltd
Collaborators
Beijing Children's Hospital
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
Jun 25, 2023
Primary completion
Oct 6, 2023
Completion
Mar 26, 2024
Last update
Nov 20, 2024

Study contacts

Xiaoling Wang
principal investigator · Beijing Children's Hospital
Li Li
principal investigator · Beijing Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion